Paris ALS Center

Hôpital de la Salpêtrière

The Paris ALS Center was created by Pr Vincent Meininger. It is devoted to the diagnosis and care of patients with ALS and other motor neuron diseases.

Hôpital de la Salpêtrière

To understand the disease mechanisms at work in ALS, our first objective was to perform clinical research and study the natural disease course of ALS. This strategy led to the first successful clinical trial in 1994. Beside our current involvement with clinical trials, we acquired an expertise in muscle biomarkers, genetics and neuroimaging.

Contact
Location
Hôpital de la Salpêtrière, Boulevard de l'Hopital, Paris, France

Our Specialists

François Salachas

Coordinator and Investigator of research

Dr. François Salachas is Coordinator and Investigator of research in Hôpital Pitié-Salpêtrière.

François Salachas
Current trials
Active
Phase ii

DAZALS trial

Industry trial
In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS (also known as MND) to understand its safety (side effects) and to determine if dazucorilant can slow down the worsening of the disease. The effects of dazucorilant will be compared to the effects of a placebo. This study is sponsored by Corcept Therapeutics.
Read more
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Completed
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more